Highlights
A novel 20-item, CTCL-specific patient-reported outcome measure, the CTCL-PRO-20, was developed through principal components analysis in 80 patients with cutaneous T-cell lymphoma.
The instrument demonstrated strong internal consistency overall (Cronbach’s α=0.93) and across five domains: self-consciousness, treatment burden, lack of CTCL resources, sleep/fatigue, and skin concerns.
Convergent validity appeared strongest with CTCL-relevant and dermatology-focused quality-of-life tools, including MF/SS-CTCL QoL and Skindex-29, while correlations were lower with generic or single-domain instruments.
Higher CTCL-PRO-20 scores, indicating poorer quality of life, were associated with progressive disease and with receipt of systemic and topical treatment, supporting preliminary construct validity.
Background and unmet need
Cutaneous T-cell lymphoma (CTCL) comprises a heterogeneous group of extranodal non-Hodgkin lymphomas characterized by malignant skin-homing T cells. Mycosis fungoides (MF) and Sézary syndrome (SS) are the best-known subtypes. Although CTCL is rare, its clinical burden is often substantial and chronic. Patients may experience pruritus, pain, scaling, dyspigmentation, visible lesions, sleep disruption, fatigue, treatment-related inconvenience, social embarrassment, and uncertainty related to disease course. Even when disease is not immediately life-threatening, day-to-day functioning may be deeply affected.
This gap between traditional clinical endpoints and lived patient experience is particularly relevant in CTCL. Clinicians often follow skin response, stage, progression, blood involvement, and treatment toxicity; however, these metrics do not fully capture the psychosocial and functional toll of visible skin disease and prolonged therapy. Existing quality-of-life (QoL) instruments used in CTCL research have generally been either generic health-status measures or dermatology-focused tools not designed specifically for CTCL. As a result, they may miss disease-specific burdens such as repeated skin-directed regimens, prolonged follow-up, limited access to specialized information, and the stigma of visible lymphoma.
The study by Akkad and colleagues addresses this unmet need by developing and preliminarily validating a CTCL-specific QoL survey: the CTCL-PRO-20. The central question is not simply whether patients with CTCL have impaired QoL, which is already well recognized, but whether a concise, psychometrically coherent, disease-specific instrument can quantify that burden in a clinically meaningful way.
Study design
Design and setting
This was a cross-sectional, single-center survey study involving 80 patients with CTCL. The publication reports the development and preliminary validation of the CTCL-PRO-20 using an iterative psychometric approach.
Instrument development approach
The authors used principal components analysis (PCA), an established dimension-reduction method commonly applied in scale development, to identify the underlying structure of candidate questionnaire items. Through an iterative process, they arrived at a five-component solution containing 20 items.
Domains retained in the final CTCL-PRO-20
The final instrument included the following domains: self-consciousness, treatment burden, lack of CTCL resources, sleep/fatigue, and skin concerns. These domains are clinically plausible and reflect major dimensions of CTCL burden that are often observed in practice but are incompletely measured by generic tools.
Psychometric and clinical validation strategy
The investigators assessed internal consistency reliability using Cronbach’s alpha and examined convergent validity by correlating CTCL-PRO-20 scores with other QoL measures. They also evaluated construct validity by comparing scores across clinically distinct groups, including disease activity status and treatment exposure.
Comparators and anchors
According to the abstract, stronger correlations were found with more disease-relevant QoL measures such as MF/SS-CTCL QoL and Skindex-29, and weaker correlations were observed with the generic SF-36 and with narrower single-focus instruments such as sleep disturbance measures. This is an important validation strategy: a disease-specific instrument should correlate with related constructs, but not so strongly with generic tools that it appears redundant.
Key results
Scale structure and reliability
The CTCL-PRO-20 demonstrated high overall internal consistency reliability, with Cronbach’s α=0.93. In practical terms, this suggests that the 20 items work together coherently as a summary measure of CTCL-related QoL impairment. Domain-level reliability was also favorable:
Self-consciousness: α=0.94
Treatment burden: α=0.92
Lack of CTCL resources: α=0.74
Sleep/fatigue: α=0.87
Skin concerns: α=0.88
These values support the internal coherence of most subscales, with particularly strong performance for self-consciousness and treatment burden. The lack of CTCL resources domain had a lower alpha than the others, but 0.74 remains acceptable for an emerging instrument, especially in a rare-disease setting where item breadth may be important.
Why these domains matter clinically
The five domains are noteworthy because they align with real-world CTCL care. Self-consciousness captures the psychosocial burden of visible skin disease, which may affect work, intimacy, and social participation. Treatment burden reflects the cumulative demands of topical regimens, clinic visits, phototherapy, systemic therapy, and prolonged symptom management. Lack of CTCL resources points to a less frequently measured but highly relevant concern in rare disease: patients often struggle to find trustworthy information and specialized support. Sleep/fatigue captures the systemic and symptomatic consequences of itch and chronic disease. Skin concerns remain central in CTCL because lesions are not only diagnostic and prognostic markers, but also a constant source of discomfort and body-image distress.
Convergent validity
The authors report high Pearson correlations between the CTCL-PRO-20 and measures more closely aligned with patients’ CTCL experiences, including MF/SS-CTCL QoL and Skindex-29. This pattern supports convergent validity: the new instrument appears to measure a construct similar to other dermatology- and CTCL-relevant QoL tools.
By contrast, lower correlations were observed with the SF-36, a generic health-related QoL instrument, and with single-domain measures such as sleep disturbance scales. This is exactly the pattern one would hope to see from a useful disease-specific tool. If correlations with generic tools were equally high, the case for a CTCL-specific measure would be weaker. Instead, the observed gradient suggests that CTCL-PRO-20 may capture unique aspects of disease burden that are diluted or missed by broad population instruments.
Known-groups comparisons and construct validity
The study also explored whether the instrument distinguished between clinically different patient groups. Patients with stable or no active disease, compared with those with progressive disease, reported significantly lower treatment-burden scores, indicating better QoL in that domain. This finding is intuitive: patients with worsening CTCL typically require more intensive or disruptive treatment strategies and may perceive disease management as more onerous.
In addition, patients receiving systemic and topical treatments, compared with those receiving no treatment, had significantly higher CTCL-PRO-20 scores, indicating poorer QoL. This finding deserves careful interpretation. It does not necessarily mean that treatment itself worsens quality of life in a causal sense. More likely, treatment intensity is acting partly as a proxy for disease severity, symptom burden, or both. Patients who need systemic or combination treatment often have more active, extensive, or refractory disease, and that clinical context may explain much of the QoL decrement.
Even so, the result is clinically important. It suggests that the questionnaire is sensitive to the lived consequences of disease management, not merely the presence of skin lesions. In CTCL, where long-term therapy often includes time-consuming topical applications, phototherapy schedules, or systemic adverse effects, treatment burden is a major component of patient experience and should not be marginalized as secondary.
Clinical interpretation
What this study adds
This work is important because it moves CTCL outcomes assessment closer to disease-specific, patient-centered measurement. In rare cancers, instrument development is difficult: sample sizes are small, phenotypes are heterogeneous, and multicenter validation often lags behind clinical need. A concise 20-item survey with strong initial psychometric properties is therefore a meaningful contribution.
The CTCL-PRO-20 may be especially useful in three settings. First, in clinical practice, it could help identify which patients are most affected by psychosocial distress, fatigue, treatment burden, or skin-related symptoms despite apparently stable disease. Second, in clinical trials, it may provide a more sensitive endpoint than generic QoL tools when evaluating treatments intended to relieve symptoms or reduce management complexity. Third, in health services research, it may help quantify unmet needs around education, support, and access to CTCL-specific resources.
Potential advantages over existing measures
Generic measures such as the SF-36 remain valuable for broad health comparisons, but they often underperform when the burden is highly disease-specific, visible, and symptom-driven. Dermatology measures like Skindex-29 capture skin-related suffering but are not tailored to the oncology-specific realities of CTCL. CTCL-specific instruments, if validated rigorously, may better detect meaningful change in domains that matter most to patients and clinicians. The inclusion of treatment burden and access to resources is particularly forward-looking, since both may influence adherence, satisfaction, and shared decision-making.
Methodological strengths and limitations
Strengths
The study has several strengths. It focuses on a clear unmet measurement need in a rare malignancy. It uses a systematic item-reduction and dimensionality approach. It reports internal consistency at both total-scale and subscale levels. It also examines convergent and construct validity using clinically relevant comparators and known-group differences. For an early validation study, these are appropriate and informative steps.
Limitations
The most important limitation is the single-center, cross-sectional design. A sample of 80 patients is understandable in rare-disease research, but still modest for psychometric validation. Single-center recruitment may limit representativeness with respect to CTCL subtype distribution, stage, socioeconomic context, race and ethnicity, treatment patterns, and referral bias.
Cross-sectional data also cannot establish responsiveness, which is one of the most clinically important properties of a patient-reported outcome measure. It remains unknown how well CTCL-PRO-20 detects change after treatment escalation, symptom improvement, remission, or relapse. Similarly, test-retest reliability is not described in the abstract, so stability over short intervals in unchanged patients is not yet established.
Another interpretive challenge is disentangling disease burden from treatment burden. Higher scores among treated patients may reflect more severe disease, more toxic therapy, or both. Future analyses will need to address this using larger cohorts, longitudinal follow-up, and possibly stratification by stage, subtype, itch severity, and treatment modality.
Finally, principal components analysis is a common starting point in scale development, but more advanced psychometric work is still needed. Confirmatory factor analysis, item-response theory approaches, assessment of floor and ceiling effects, and determination of minimal clinically important difference would all strengthen the instrument’s readiness for widespread use.
How this fits with the broader literature
Prior studies have consistently shown that CTCL can profoundly impair quality of life, particularly through pruritus, disfigurement, social isolation, fatigue, and emotional distress. International treatment guidelines for MF and SS increasingly emphasize symptom control, skin-directed palliation, and individualized care, all of which support the need for robust patient-reported outcome assessment. Dermatology-specific QoL tools have been helpful, but a disease-specific measure is likely to be more aligned with the complexity of CTCL management.
In that context, the CTCL-PRO-20 appears to represent a pragmatic next step rather than a replacement for all existing tools. In research, it may complement clinician-reported response criteria and symptom-specific instruments. In routine care, it could help operationalize supportive care needs that are otherwise discussed qualitatively but not measured systematically.
Implications for practice and research
Near-term clinical use
Clinicians should view the CTCL-PRO-20 as promising but still preliminary. It is not yet the definitive QoL standard for CTCL, but it offers a potentially more relevant framework for patient assessment than generic tools alone. The domains may also guide structured clinical conversations even before the instrument is fully adopted. Asking directly about self-consciousness, fatigue, sleep, treatment burden, and difficulty finding CTCL resources may uncover actionable concerns that standard disease review misses.
Next validation priorities
The next phase of work should include multicenter validation across diverse CTCL populations, including different stages and subtypes, and ideally across community and academic settings. Longitudinal studies should determine responsiveness to treatment change, relapse, and symptom fluctuations. Investigators should also define score interpretation thresholds, including what constitutes mild, moderate, and severe QoL impairment, and establish the minimal clinically important difference for use in interventional trials.
Translation and cross-cultural adaptation will also be important if the tool is to support international studies. Because CTCL is rare, harmonization across centers and countries may ultimately be necessary to achieve the sample sizes needed for full psychometric confirmation.
Funding and ClinicalTrials.gov
The abstract and PubMed entry provided do not report funding details or a ClinicalTrials.gov registration number. As described, this appears to be an observational survey-based validation study rather than a registered therapeutic trial. Readers should consult the full Haematologica publication for any additional disclosures, funding statements, and conflict-of-interest information.
Conclusion
The CTCL-PRO-20 is an encouraging new disease-specific quality-of-life instrument for patients with cutaneous T-cell lymphoma. In this preliminary single-center study, it showed strong internal consistency, clinically coherent domain structure, and supportive evidence of convergent and construct validity. Its strongest value lies in measuring dimensions of CTCL burden that matter deeply to patients but are incompletely captured by generic health-status tools, especially self-consciousness, treatment burden, sleep/fatigue, skin concerns, and lack of disease-specific resources.
The findings are not yet sufficient to establish the CTCL-PRO-20 as a definitive standard, but they do justify larger and longitudinal validation. If future studies confirm responsiveness and generalizability, this tool could become a useful endpoint in CTCL trials and a practical instrument for routine patient-centered care.
Citation
Akkad N, Jeffe DB, Krause A, Al-Hammadi N, Watkins M, Musiek A, Mehta-Shah N. The development and preliminary validation of the CTCL-PRO-20: a novel quality of life survey for patients with cutaneous T-cell lymphoma. Haematologica. 2026-05-07. PMID: 42095261. Available at: https://pubmed.ncbi.nlm.nih.gov/42095261/
Selected related references
Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2017;77:57-74.
Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the EORTC. J Clin Oncol. 2011;29(18):2598-2607.
Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105-110.
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-483.